Literature DB >> 27509124

Assessment of Minimal Residual Disease in Standard-Risk AML.

Robert K Hills, Adam Ivey, David Grimwade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27509124     DOI： 10.1056/NEJMc1603847

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

Authors:  Fei Yang; Tauangtham Anekpuritanang; Richard D Press
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

Review 3.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

4.  Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes.

Authors:  Rafael Diaz de la Guardia; Belen Lopez-Millan; Jessie R Lavoie; Clara Bueno; Julio Castaño; Maite Gómez-Casares; Susana Vives; Laura Palomo; Manel Juan; Julio Delgado; Maria L Blanco; Josep Nomdedeu; Alberto Chaparro; Jose Luis Fuster; Eduardo Anguita; Michael Rosu-Myles; Pablo Menéndez
Journal:  Stem Cell Reports       Date:  2017-05-18       Impact factor: 7.765

5.  The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.

Authors:  Mario Petrini; Sara Galimberti; Serena Salehzadeh; Francesca Guerrini; Umberto Pizzano; Susanna Grassi; Elena Ciabatti; Lorenzo Iovino; Gabriele Buda; Francesco Caracciolo; Edoardo Benedetti; Enrico Orciuolo; Matteo Pelosini; Giovanni Consani; Giovanni Carulli; Maria Rita Metelli; Francesca Martini; Francesco Mazziotta; Elisa Mazzantini; Pietro Rossi; Rita Tavarozzi; Federica Ricci
Journal:  Cancer Cell Int       Date:  2019-04-04       Impact factor: 5.722

Review 6.  Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse.

Authors:  Amandeep Salhotra; Anthony Selwyn Stein
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

7.  Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.

Authors:  Sijian Yu; Zhiping Fan; Liping Ma; Yu Wang; Fen Huang; Qing Zhang; Jiafu Huang; Shunqing Wang; Na Xu; Li Xuan; Mujun Xiong; Lijie Han; Zhiqiang Sun; Hongyu Zhang; Hui Liu; Guopan Yu; Pengcheng Shi; Jun Xu; Meiqing Wu; Ziwen Guo; Yiying Xiong; Chongyang Duan; Jing Sun; Qifa Liu; Yu Zhang
Journal:  JAMA Netw Open       Date:  2021-07-01

Review 8.  Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia.

Authors:  M Ryan Corces; Howard Y Chang; Ravindra Majeti
Journal:  Front Oncol       Date:  2017-11-06       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.